Simponi® (golimumab)

BL 125289

Simponi® (golimumab)

BL 125289

U.S. License Holder:

Centocor Ortho Biotech Inc. (Janssen Biotech, Inc.)

Date of License:

April-24-2009

Last Update:

Nov-15-2024

approved_indications FDA-Approved Indications

SIMPONI (golimumab) is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with:

Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate;

Active psoriatic arthritis (PsA) alone, or in combination with methotrexate;

Active ankylosing spondylitis (AS);

Moderate to severe Ulcerative colitis (UC) with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy: inducing and maintaining clinical response; improving endoscopic appearance of the mucosa during induction; inducing clinical remission; achieving and sustaining clinical remission in induction responders.

approved_indications U.S. Patent Litigations

PACER

Case No(s):

4:09-cv-11362 (D. Mass.)

U.S. Patent Nos.
5,654,407 (Human Anti-TNF Antibodies)

Plaintiffs
Bayer Healthcare, LLC

Defendants
Centocor Ortho Biotech, Inc.

Federal Circuit Appeal(s)
11-1207

Status
Case Terminated

BPCIA
N

4:09-cv-40089 (D. Mass.)

U.S. Patent Nos.
7,223,394 (Human Antibodies that Bind Human TNF-Alpha) 7,541,031 (Methods for Treating Rheumatoid Arthritis using Human Antibodies that Bind Human TNF-Alpha)

Plaintiffs
AbbVie Biotechnology Ltd.; AbbVie Inc.; Abbott Laboratories

Defendants
Centocor Ortho Biotech, Inc.

Status
Dismissed

BPCIA
N

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha